vs
Side-by-side financial comparison of STURM RUGER & CO INC (RGR) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $151.1M, roughly 1.0× STURM RUGER & CO INC). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 3.6%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $12.3M).
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
RGR vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.1M | $158.6M |
| Net Profit | — | $112.9M |
| Gross Margin | 17.8% | — |
| Operating Margin | 2.3% | 70.2% |
| Net Margin | — | 71.2% |
| Revenue YoY | 3.6% | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $0.22 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.1M | — | ||
| Q3 25 | $126.8M | — | ||
| Q2 25 | $132.5M | — | ||
| Q1 25 | $135.7M | $158.6M | ||
| Q4 24 | $145.8M | $22.6M | ||
| Q3 24 | $122.3M | — | ||
| Q2 24 | $130.8M | — | ||
| Q1 24 | $136.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $-17.2M | — | ||
| Q1 25 | $7.8M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $4.7M | — | ||
| Q2 24 | $8.3M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | 17.8% | — | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 22.0% | — | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | 22.3% | — | ||
| Q1 24 | 21.5% | — |
| Q4 25 | 2.3% | — | ||
| Q3 25 | -2.7% | — | ||
| Q2 25 | -15.6% | — | ||
| Q1 25 | 6.2% | 70.2% | ||
| Q4 24 | 7.8% | -60.4% | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 6.9% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | -13.0% | — | ||
| Q1 25 | 5.7% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | 5.2% | — |
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $-1.05 | — | ||
| Q1 25 | $0.46 | $1.90 | ||
| Q4 24 | $0.62 | $-0.15 | ||
| Q3 24 | $0.28 | — | ||
| Q2 24 | $0.47 | — | ||
| Q1 24 | $0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $283.8M | $350.1M |
| Total Assets | $342.0M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.5M | — | ||
| Q3 25 | $80.8M | — | ||
| Q2 25 | $101.4M | — | ||
| Q1 25 | $108.3M | $274.8M | ||
| Q4 24 | $105.5M | $128.0M | ||
| Q3 24 | $96.0M | — | ||
| Q2 24 | $105.6M | — | ||
| Q1 24 | $115.3M | — |
| Q4 25 | $283.8M | — | ||
| Q3 25 | $279.6M | — | ||
| Q2 25 | $289.3M | — | ||
| Q1 25 | $321.5M | $350.1M | ||
| Q4 24 | $319.6M | $229.0M | ||
| Q3 24 | $314.9M | — | ||
| Q2 24 | $321.5M | — | ||
| Q1 24 | $332.0M | — |
| Q4 25 | $342.0M | — | ||
| Q3 25 | $342.3M | — | ||
| Q2 25 | $349.5M | — | ||
| Q1 25 | $379.0M | $406.9M | ||
| Q4 24 | $384.0M | $271.6M | ||
| Q3 24 | $373.5M | — | ||
| Q2 24 | $376.7M | — | ||
| Q1 24 | $385.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.5M | $131.8M |
| Free Cash FlowOCF − Capex | $12.3M | $131.7M |
| FCF MarginFCF / Revenue | 8.2% | 83.0% |
| Capex IntensityCapex / Revenue | 2.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $38.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $14.7M | — | ||
| Q1 25 | $11.1M | $131.8M | ||
| Q4 24 | $20.0M | $-23.2M | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $18.7M | — | ||
| Q1 24 | $7.3M | — |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $10.0M | $131.7M | ||
| Q4 24 | $16.4M | $-23.2M | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $10.1M | — | ||
| Q1 24 | $5.6M | — |
| Q4 25 | 8.2% | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 7.4% | 83.0% | ||
| Q4 24 | 11.2% | -102.7% | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 7.7% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 2.5% | 0.2% | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.15× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.43× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.98× | — | ||
| Q2 24 | 2.27× | — | ||
| Q1 24 | 1.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
STOK
Segment breakdown not available.
